Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.

Shattuck Labs, Inc. ($STTK) announced an update on their ongoing clinical study. Shattuck Labs, Inc. is launching a mid stage study called “A Phase...

Shattuck Labs Advances SL-325 Crohn’s Trial Toward a Key Value Milestone

In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Shattuck Labs, with a price target of $11.00. According to T...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	STTK	$6.79	-2.44%	677.76K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	STTK	$6.79	-2.4%	677.76K
3
4
5
6

STTK

Get Shattuck Labs, Inc. Data in Excel

Get Shattuck Labs, Inc. Data in Excel